Antibacterial activities of SM-1652 compared with those of other broad-spectrum cephalosporins.

Antimicrobial Agents and Chemotherapy
M KatoS Mitsuhashi

Abstract

The in vitro and in vivo activities of Sm-1652 were compared with those of other cephalosporins. SM-1652 possessed a wide antibacterial spectrum which included activity against Pseudomonas aeruginosa. It also exhibited potent antibacterial activities against gram-positive cocci and clinical isolates of glucose nonfermentative bacteria. Most notably, its activity against glucose nonfermentative bacteria was the highest of all of the drugs tested. The bactericidal activity of SM-1652 was compared with that of cefoperazone. The difference between the minimum bactericidal concentration and the minimum inhibitory concentration of SM-1652 was actually smaller than that of cefoperazone for Escherichia coli and clinical isolates of indole-positive Proteus spp. SM-1652 was stable for most cephalosporinases but was hydrolyzed to some extent by penicillinases. The in vivo therapeutic effect of SM-1652 against infections in mice was better than those of cefazolin and cefoxitin. The in vivo antipseudomonal activity of SM-1652 was second to that of cefsulodin.

References

Dec 1, 1979·Antimicrobial Agents and Chemotherapy·N MatsubaraS Mitsuhashi
Feb 1, 1978·Antimicrobial Agents and Chemotherapy·K TsuchiyaH Nagatomo
Jun 1, 1974·The Biochemical Journal·S G Waley
Aug 1, 1981·Antimicrobial Agents and Chemotherapy·K HiraiS Mitsuhashi
Jul 1, 1980·Antimicrobial Agents and Chemotherapy·S MinamiS Mitsuhashi

❮ Previous
Next ❯

Citations

Aug 1, 1988·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·C QuentinM Titonel
Apr 1, 1985·European Journal of Clinical Microbiology·A L BarryC Thornsberry
Jan 1, 1986·Diagnostic Microbiology and Infectious Disease·R J Fass, V L Helsel
Feb 1, 1984·Antimicrobial Agents and Chemotherapy·H WexlerS M Finegold
Feb 1, 1984·Antimicrobial Agents and Chemotherapy·K NakagawaT Noguchi
Mar 1, 1984·Antimicrobial Agents and Chemotherapy·M A PfallerP R Murray
Sep 1, 1984·Antimicrobial Agents and Chemotherapy·M FuksaA Lee
May 1, 1985·Antimicrobial Agents and Chemotherapy·J D AllanR C Moellering
Nov 1, 1985·Diagnostic Microbiology and Infectious Disease·H C Neu, N X Chin
Oct 1, 1985·Journal of Clinical Microbiology·A L BarryR N Jones

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.